Johnson & Johnson’s immunology drug Tremfya is looking to challenge AbbVie’s dominance in 2026, securing the top spot as the biggest TV drug ad spender in March. J&J spent $50.3 million on TV ads for ...
After losing the top spot in March to Johnson & Johnson’s immunology drug Tremfya, AbbVie’s rival med Skyrizi is back as the drug with the highest level of ad spending. AbbVie shelled out $46.8 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results